EMA Consults On Extrapolation Considerations For Antibacterial Agents To Treat Pediatrics
Executive Summary
Draft guidance from the European Medicines Agency explains what data companies should generate when they seek marketing approval for antibacterial agents for treating children, including whether pharmacokinetic data in a limited number of pediatric subjects may be suffice to grant a pediatric indication.
You may also be interested in...
Increase In Antibacterial R&D Prompts EMA Proposal For Improved Guidance
Following a resurgence of activity in the field of antibacterial products, the European Medicines Agency has proposed merging and updating its two existing guidelines on this topic into a single, clearer, core document.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EMA Hopes New Requirement Will Make Companies Stick To Their Filing Plans
An additional form that marketing authorization applicants must now complete during the pre-submission stage emphasizes the importance of companies providing accurate information on their intended submission date.